Cambridge Cognition Holdings order intake above expectations (Interview)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk Interviews to discuss interim results for the six months ended 30th June 2021. Matthew talks us through the highlights, explains the increase in sales orders of 74% to £8.6 million, the effect of a successful spin-out and venture financing of Monument Therapeutics, what the launch of NeuroVocalix™ which is now ready for clinical trials means for the company and what we can expect from the company going forward.

Cambridge Cognition Holdings is a world leading neuroscience technology company committed to enhancing global research, accelerating treatment development and improving patient outcomes in conditions affecting brain health by optimising the assessment of cognition.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition AGM to be held on 27 May 2021

Cambridge Cognition Holdings plc (LON:COG) which develops and markets digital solutions to assess brain health, has confirmed that the Annual Report and Accounts for the year ended 31 December 2020 and the Notice of the Annual

Cambridge Cognition Holdings

Cambridge Cognition Strong financial performance revenues up 34%

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced a positive trading update and notice of results for the year ended 31 December 2020, together with details of a forthcoming

Cambridge Cognition Holdings

Cambridge Cognition wins new £750,000 digital health contract

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won a new contract providing cognitive tests and electronic clinical outcome assessments for an Alzheimer’s trial.

Cambridge Cognition Holdings

Cambridge Cognition Holdings revenues up 39% to £3.01 million

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced its unaudited interim results for the six months ended 30 June 2020. The first half of 2020 saw strong progress in